

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human LMP2/PSMB9 in direct ELISAs and Western blots. In direct ELISAs, approximately 50% cross-reactivity with recombinant human PSMB6 is observed.
Source	Monoclonal Mouse IgG _{2B} Clone # 792520
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	<i>E. coli</i> -derived recombinant human LMP2/PSMB9 Thr21-Glu219 Accession # P28065
Conjugate	Alexa Fluor 488 Excitation Wavelength: 488 nm Emission Wavelength: 515-545 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

Western Blot	Optimal dilution of this antibody should be experimentally determined.
Immunocytochemistry	Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

LMP2 (large multifunctional peptidase 2), also called PSMB9 (proteasome subunit beta 9) or PSMB6i, is a 22 kDa broad-specificity aminopeptidase of the T1B family that is a component of the 20S immunoproteasome core (α7b7b7a7) of the 26S proteasome particle. Induction of LMP2 by IFN-γ, IRF-1, TNF-α, CD40L, or heat shock in immune-responsive cells or cancer cells promotes replacement of proteasome subunit PSMB6 by LMP2 and processing of peptides for presentation by MHC I. After auto-cleavage between amino acids (aa) 20-21, human LMP2 (aa 21-219) shares 91% aa sequence identity with mouse and rat LMP2. Alternate splicing creates a short form, LMP2.S, which lacks aa 4-13 within the propeptide.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.